Abatacept topic

Also known as

Orencia

Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy. Ordinarily, full T cell activation requires 1) binding of the T... full article at wikipedia

Write new description for Freebase.com

Add a type

Medicine

Medical Treatment

4 empty fields

Side effects

Contraindications

Trials

Used To Treat

Drug

10 empty fields

Edit	Pronunciation

ATC Code

Drugbank

Pubchem

Edit	CAS Number

Drug class

Brands

Route of administration

Pregnancy category

Legal status

BioVenturist | user-created view »

BV: Product

1 empty field

Technology involved

Sales

Developed by

Edit	Brand Names

Orencia

Edit	Stage of development

On the market

BV: Therapeutic

4 empty fields

Target/Biomolecule of Interest

Indication or disease

therapeutic molecule

Delivery Technology

Edit	Approval Date

With the exception of Wikipedia summaries and some images the content on this page is typically distributed under the Creative Commons Attribution license or Public Domain.

The original description for this topic was automatically generated from the Wikipedia article "Abatacept" licensed under the GNU Free Documentation License .